Ind-Swift Laboratories Limited — Others, 13-02-2025: Statement of deviation(s) or variation(s) under Reg. 32

Ind-Swift Laboratories Ltd. has confirmed no deviation in the utilization of funds raised through its preferential issue of convertible warrants, totaling ₹78.73 crores out of a total issue size of ₹314.60 crores. The Audit Committee has reviewed the Nil Statement of Deviation for the quarter ended December 31, 2024. Funds were utilized primarily for business expansion, existing subsidiary investments, and working capital, with ₹57.65 crores allocated accordingly. This transparency may foster a positive outlook among investors, reinforcing trust in the company's financial management and operational integrity.